Pluri Partners With Kadimastem to Advance Cell Therapy Products for Clinical Trials
Pluri Partners With Kadimastem to Advance Cell Therapy Products for Clinical Trials
Leading biotechnology company Pluri Inc. (NASDAQ:PLUR) (TASE:PLUR) ("Pluri" or the "Company"), which transforms cells into solutions that promote global wellbeing and sustainability, today announced it has signed a tech transfer and manufacturing agreement with Kadimastem Ltd. (TASE: KDST), a clinical stage biotechnology company developing therapeutic cells for ALS and diabetes treatments. PluriCDMO, launched earlier this year, leverages Pluri's 47,000 square foot good manufacturing practice (GMP) cell production facility to manufacture cell-based products for life science companies.
领先的生物技术公司Pluri Inc.（纳斯达克：PLUR）（TASE：PLUR）（“ Pluri”或“公司”）将细胞转化为促进全球福祉和可持续性的解决方案。 今天宣布，已与正在开发治疗ALS和糖尿病的临床阶段生物技术公司Kadimastem Ltd.（TASE：KDST）签署技术转让和制造协议。此年初推出的PluriCDMO利用Pluri的47,000平方英尺的生产实践（GMP）细胞生产设施，为生命科学公司制造基于细胞的产品。
PluriCDMO will manufacture two cell therapy product candidates for Kadimastem: AstroRx, clinical grade human astrocytes (nervous system supporting cells) for the treatment of ALS for an upcoming U.S. Food and Drug Administration (FDA) Phase 2a study; and IsletRx, clinical grade pancreatic islet cells which produce and secrete insulin and glucagon in response to blood glucose levels, for the treatment of diabetes.
PluriCDMO将为Kadimastem制造两个细胞疗法产品候选者：AstroRx，用于即将到来的美国食品和药物管理局（FDA）第2a阶段研究的临床等级人类星形胶质细胞（神经系统支持细胞）；以及IsletRx，临床级胰岛细胞，响应于血糖水平产生和分泌胰岛素和葡萄糖原，用于治疗糖尿病。
Key to Kadimastem's selection of PluriCDMO is Pluri's unparalleled expertise and experience in developing and manufacturing cell-based products in GMP grade for clinical use. From initial clinical trial batches to mass scale commercial production, PluriCDMO is a long-term partner and service provider for the cell therapy production needs of the most innovative companies.
Kadimastem选择PluriCDMO的关键是Pluri在开发和制造GMP级别、用于临床使用的基于细胞的产品方面的无与伦比的专业知识和经验。从最初的临床试制批次到大规模商业生产，PluriCDMO是最具创新性的公司细胞疗法生产需求的长期合作伙伴和服务提供商。